SCHEMBL294734

SCHEMBL294734

O=S(=O)(Nc1nnc(C(F)(F)F)s1)c1ccc2c(c1)CC(Nc1ncc(C(F)(F)F)cc1Cl)C2

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
TDP1 Q9NUW8 1/20 0.47
HTT P42858 4/20 0.39
LMNA P02545 3/20 0.39
POLB P06746 2/20 0.39
SCN9A Q15858 10/20 0.37
MAPT P10636 3/20 0.37
XBP1 P17861 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 1/20 0.37
AHR P35869 1/20 0.36
SCN5A Q14524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL293567 0.89 KMT2A (0.45) MEN1KMT2ATDP1HTTLMNA
SCHEMBL295244 0.88 KMT2A (0.47) MEN1KMT2ATDP1HTTLMNA
SCHEMBL295358 0.88 MEN1 (0.46) MEN1KMT2ATDP1HTTLMNA
SCHEMBL294156 0.87 KMT2A (0.49) MEN1KMT2ATDP1HTTLMNA
SCHEMBL295829 0.81 KMT2A (0.51) MEN1KMT2ATDP1HTTLMNA
SCHEMBL295828 0.81 KMT2A (0.51) MEN1KMT2ATDP1HTTLMNA
SCHEMBL2772880 0.80 MEN1 (0.48) MEN1KMT2ATDP1HTTLMNA
SCHEMBL294845 0.76 POLB (0.42) MEN1KMT2ATDP1HTTLMNA
SCHEMBL1970658 0.76 CA1 (0.54) MEN1KMT2ATDP1POLBMAPT
SCHEMBL294925 0.75 POLB (0.45) MEN1KMT2ATDP1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 US disclosed
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 US disclosed
EP-2240474-B1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-03-14 EP disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
WO-2009080223-A1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals PPARD, PPARG, PPARA MEN1 4666/4885KMT2A 3682/4885TDP1 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.